US EditionBrii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
- Brii Biosciences Limited presented late-breaking Phase 2 ENSURE study data on May 7, 2025, at the EASL Congress in Amsterdam, Netherlands.
- The study investigates elebsiran combined with pegylated interferon alfa in chronic hepatitis B patients, enriched by prior BRII-179 treatment to improve outcomes.
- Cohort 4 data show anti-HBs responders induced by BRII-179 had 61% HBsAg seroclearance at end of treatment, faster and higher than non-responders including cohorts 1-3.
- At 24 weeks post-treatment, elebsiran plus PEG-IFN showed higher HBsAg loss rates versus PEG-IFN alone , with safety profiles consistent with PEG-IFN treatment.
- These findings suggest BRII-179 may identify and prime patients for a durable functional cure, potentially allowing shorter PEG-IFN treatment durations in chronic HBV infection.
Insights by Ground AI
Does this summary seem wrong?
45 Articles
45 Articles
All
Left
5
Center
16
Right
5
The Berkshire Eagle+43 Reposted by 43 other sources
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants, strengthening the case…
Coverage Details
Total News Sources45
Leaning Left5Leaning Right5Center16Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 19%
C 62%
R 19%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage